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Abstract
Although viral hepatitis treatments have evolved over 
the years, the resultant liver cirrhosis still does not 
completely heal. Platelets contain proteins required for 
hemostasis, as well as many growth factors required 
for organ development, tissue regeneration and repair. 
Thrombocytopenia, which is frequently observed 
in patients with chronic liver disease (CLD) and cir-
rhosis, can manifest from decreased thrombopoietin 
production and accelerated platelet destruction caused 
by hypersplenism; however, the relationship between 
thrombocytopenia and hepatic pathogenesis, as well 
as the role of platelets in CLD, is poorly understood. In 
this paper, experimental evidence of platelets improving 
liver fibrosis and accelerating liver regeneration is 
summarized and addressed based on studies conducted 
in our laboratory and current progress reports from 
other investigators. In addition, we describe our current 
perspective based on the results of these studies. 
Platelets improve liver fibrosis by inactivating hepatic 
stellate cells, which decreases collagen production. The 
regenerative effect of platelets in the liver involves a 
direct effect on hepatocytes, a cooperative effect with 
liver sinusoidal endothelial cells, and a collaborative 
effect with Kupffer cells. Based on these observations, 
we ascertained the direct effect of platelet transfusion 
on improving several indicators of liver function in 
patients with CLD and liver cirrhosis. However, unlike 
the results of our previous clinical study, the smaller 
incremental changes in liver function in patients with 
CLD who received eltrombopag for 6 mo were due to 
patient selection from a heterogeneous population. We 
highlight the current knowledge concerning the role 
of platelets in CLD and cancer and anticipate a novel 
application of platelet-based clinical therapies to treat 
liver disease.
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Core tip: Platelets improve liver fibrosis and accelerate 
liver regeneration; therefore, patients with liver 
dysfunction due to chronic liver disease (CLD) and 
cirrhosis can benefit from platelet transfusion. However, 
administration of the thrombopoietin receptor agonist 
eltrombopag for 6 mo did not result in the improvement 
of liver function in patients with CLD despite its long-
term safety and ability to maintain an increased platelet 
count. We believe that this difference is due to platelet 
aging. Therefore, we are pursuing novel strategies 
with thrombopoietin receptor agonists and desialylated 
formulations to treat liver diseases.
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INTRODUCTION
Chronic liver disease (CLD) refers to a long-term 
pathological process of continuous destruction of 
liver parenchyma and its gradual substitution with 
fibrous tissue, which ultimately results in liver cirrhosis 
associated with a fatal outcome. CLD has diverse 
etiologies, which include hepatotrophic viruses, 
chemicals, alcohol and drug abuse, autoimmune 
disorders, cholestasis and metabolic diseases[1,2], and 
it is a major cause of morbidity and mortality in many 
countries[3,4]. Hepatocellular carcinoma (HCC) is a 
dominant complication of CLD and cirrhosis, with the 
third highest death rate among malignancies in the 
world[5]. 
HCC was shown to significantly correlate with 
advanced fibrosis, as a sustained wound-healing 
response to hepatitis C virus infection; however, 
despite the progress in viral hepatitis therapies, 
they are unable to completely heal hepatocellular 
injuries and prevent liver cirrhosis[6]. At present, liver 
transplantation is the only treatment option for end-
stage liver failure, but its clinical availability is hindered 
by serious problems such as donor shortage, surgical 
complications, graft rejection and high cost[1,7-11]. 
Therefore, other therapeutic approaches are being 
looked into; among them, measures to resolve liver 
fibrosis have been investigated. 
Liver fibrosis is caused by a continuous excessive 
deposition of the extracellular matrix (ECM) in 
response to chronic liver injury[1,2]. Although advanced 
liver fibrosis has been considered irreversible, resulting 
in permanent substitution of hepatocytes with the 
ECM components, recent reports indicate that certain 
immunotherapies may promote partial resolution 
of liver cirrhosis[12-15]. These studies encourage the 
development of novel approaches to treat patients 
with advanced CLD. 
Thrombocytopenia, i.e., the reduction of platelet 
count in blood, is a common hematological complication 
of CLD caused by decreased production of hormone 
thrombopoietin (TPO) in the damaged liver and/or 
increased destruction of platelets through phagocytosis 
in the enlarged spleen, as well as the loss of hema-
topoietic function in bone marrow due to alcohol abuse 
or viral infection[16-19]. Platelets are anuclear blood cells 
derived from TPO-stimulated megakaryocytes; they not 
only play a critical role in hemostasis, but also secrete 
several growth factors, including platelet-derived growth 
factor (PDGF) and hepatocyte growth factor (HGF), 
which promote liver regeneration[20-25]. As a feedback 
response, thrombocytopenia further aggravates hepatic 
destruction and contributes to the pathogenesis of CLD 
and cirrhosis, suggesting that measures to prevent 
platelet loss may be useful as a therapeutic approach to 
treat CLD.
Indeed, our previous studies in experimental 
animal models revealed that platelets play a crucial 
role in promoting liver regeneration after hepatectomy 
by inducing hepatocyte proliferation[26-29] and stopping 
the progression of liver fibrosis[30-32]. Furthermore, in 
patients with CLD and cirrhosis, platelet transfusion 
and splenectomy used as a platelet increment therapy, 
positively affected hepatic function[33-35]. Along these 
lines, we have investigated the safety of long-term 
administration of the TPO receptor (TPO-R) agonist 
eltrombopag for treating patients with CLD. 
However, the effect of thrombocytopenia on 
liver damage and exact mechanisms underlying 
thrombocytopenia in patients with CLD and cirrhosis 
are still unclear and require further study to confirm 
the clinical utility of increasing platelets in CLD. 
The aim of this editorial is to summarize the current 
perspectives of novel approaches to treat liver cirrhosis 
based on augmentation of platelet counts using TPO-R 
agonists.
LIVER FIBROSIS AND PLATELETS
Liver fibrogenesis is triggered by destruction of 
hepatic cells and represents a wound-healing process 
leading to excessive deposition of the matrix proteins 
collagens and elastin, glycoproteins, proteoglycans and 
carbohydrates; in the context of chronic liver injury, 
fibrosis ultimately results in the substitution of liver 
tissue with ECM, formation of scar tissue, and gradual 
ceasing of hepatic functions[1,36]. Histologically, liver 
consists of parenchymal hepatocytes (70%-80%) 
and non-parenchymal cells such as Kupffer cells, 
sinusoidal endothelial cells and stellate cells. Hepatic 
stellate cells (HSCs) reside in the perisinusoidal 
space of the liver, also known as the space of Disse, 
between hepatocytes and sinusoidal endothelial cells 
and are the major fibrogenic cell type in the liver as 
they produce a large number of ECM components and 
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secrete transforming growth factor-β (TGF-β), a key 
mediator of liver fibrogenesis[1,36]. 
In the normal liver, HSCs have a star-like mor-
phology corresponding to a quiescent state, and their 
primary function is the storage of vitamin A as retinol 
ester in lipid droplets[37,38]. In response to liver injury, 
HSCs undergo activation and change into contractile 
myofibroblastic cells, which proliferate, secrete TGF-β, 
and increase matrix production. As a result, collagens 
Ⅳ and Ⅵ in the space of Disse are progressively 
replaced by fibrous collagens Ⅰ and Ⅲ and fibronectin, 
characteristic for ECM remodeling and fibrosis[39,40]. 
In our previous study, we revealed a link bet-
ween the activation of human HSCs and platelets by 
showing that platelets and platelet-derived extracts 
suppressed transdifferentiation of quiescent HSCs 
into the myofibroblast-like phenotype as well as the 
production of collagen type Ⅰ via cAMP signaling[31]. 
The underlying mechanism is based on the increase 
of adenosine concentration in the HSC milieu due 
to breakdown of ADP and ATP, which are abundant 
in platelet-dense granules[31]. As a result, adenosine 
entering HSCs through its cognate receptors prevents 
their activation and down-regulates their ability to 
secrete TGF-β and deposit the ECM. In addition, 
interaction between HSCs and platelets promotes the 
release of platelet-derived HGF, which was shown to 
inhibit the expression of type Ⅰ collagen in cultured 
HSCs[41] and to attenuate liver fibrosis in mice by 
decreasing hepatic TGF-β secretion and blocking 
myofibroblast activation[42]. However, although these 
findings indicate that platelets can reduce hepatic 
fibrogenesis through inhibition of HSC activation, it is 
unclear whether they can be translated to the clinical 
situation, as the production of HGF by human platelets 
is lower than that by rodent platelets[43]. 
TPO is the most important factor in the regulation 
of megakaryocyte proliferation and differentiation into 
platelets through activation of its cognate receptor 
c-Mpl, also known as TPO-R[44]. Several agonists of the 
c-Mpl receptor, such as eltrombopag and romiplostim, 
are approved for clinical application as agents by 
which to increase platelet counts in chronic immune 
thrombocytopenia[44,45]. Moreover, they are currently 
undergoing clinical trials as treatment options to 
reduce thrombocytopenia in patients with CLD and 
liver cirrhosis[46-48], as the increase in platelet counts 
could make these patients eligible for interferon-based 
antiviral therapy[49,50]. 
The strategy to treat liver fibrosis in CLD through 
inhibition of thrombocytopenia was proved feasible 
in studies showing that TPO improved both platelet 
counts and liver fibrosis, even in conditions of 
hepatic cirrhosis[30,32]. Thus, in cirrhotic rats with 
dimethylnitrosamine-induced liver fibrosis and 70% 
hepatectomy, platelet increase by a single intravenous 
injection of TPO correlated with the inhibition of 
HSC activation and decrease of the fibrotic area 
in the liver, while antiplatelet serum attenuated 
hepatic regeneration[30]. In another study, mice with 
liver fibrosis induced by carbon tetrachloride (CCl4) 
showed improvement after weekly intraperitoneal 
administration of TPO for 5-8 wk[32]. 
Although mechanistic insights into the correlation 
of increased platelet counts with the reversal of liver 
fibrosis are yet to be provided, it can be suggested 
that platelets may promote hepatocyte proliferation 
by secreting HGF, which is a potent mitogen for 
hepatocytes through activation of the MET receptor 
that is essential for organogenesis and wound healing. 
Moreover, HGF may contribute to the resolution of 
fibrosis by modulating levels of TGF-β and matrix 
metalloproteinases (MMPs), which are the main ECM 
enzymes degrading collagen. 
The suggested association between platelets, HGF, 
and hepatic fibrosis is supported by the findings of 
Takahashi et al[51], who showed that transfused human 
platelets improved CCl4-induced liver fibrosis in severe 
combined immune deficiency mice by increasing 
HGF levels in the mouse liver, which suppressed HSC 
activation, induced MMP-9 expression and inhibited 
hepatocyte apoptosis.
Liver regeneration and platelets
Liver regeneration is provided by the proliferation of 
both parenchymal and non-parenchymal hepatic cells, 
including hepatocytes, liver sinusoidal endothelial 
cells (LSECs), biliary epithelial and Kupffer cells, and 
HSCs, which contribute to the restoration of destroyed 
hepatic tissue[52]. Cell proliferation is triggered by 
several growth factors and cytokines, such as HGF, 
TGF-α, tumor necrosis factor-α (TNF-α), epidermal 
growth factor (EGF) and interleukin-6 (IL-6), which 
activate their cognate receptors and, consequently, 
downstream signaling and transcription of the genes 
associated with cell cycle progression[52-58]. Among the 
signaling cascades mediating platelet effects on the 
process of liver regeneration, the most important are 
TNF-α/nuclear factor-kappa B (NF-κB), IL-6/signal 
transducer and activator of transcription 3 STAT3, and 
phosphatidylinositol-3-kinase (PI3K)/Akt. 
 Previous studies indicate that platelets can 
exert positive effects on liver regeneration through 
cooperation with LSECs and Kupffer cells, and direct 
interaction with hepatocytes.
LSECs mostly consist of sinusoidal cells which, 
through formation of a continuous thin layer of the 
sinusoidal endothelium, create a structural barrier 
between the hepatic parenchyma and blood flowing 
through the liver[59,60]. LSECs play an important role 
in the maintenance of hepatic functions by providing 
exchange of nutrients between circulating blood and 
hepatocytes because of the presence of open pores 
beneath the endothelium[61]. In addition, LSECs secrete 
immunoregulatory cytokines, including HGF, IL-1, IL-6 
and interferons, affecting liver regeneration. Thus, 
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impact of platelet-Kupffer cell interaction in liver fibrosis. 
However, it is evident that the contact between platelets 
and Kupffer cells cause activation of both cells.
Finally, platelets can induce hepatic regeneration 
by directly interacting with hepatocytes. Thus, in 
thrombocytotic BALB/c mice, platelets accumulate 
in the liver shortly after liver resection, causing the 
regeneration of hepatic tissue even following 90% 
hepatectomy and preventing liver failure by promoting 
cell cycle progression and metabolic pathways in 
hepatocytes[77]. Such stimulation of hepatocyte 
activity is likely a result of platelet accumulation in 
the sinusoidal space, from where they flow into the 
space of Disse and directly contact hepatocytes[26-28]. 
These findings suggest that following hepatic injury, 
platelets quickly migrate to the liver where they, 
through direct interaction with hepatocytes, activate 
cell cycle transition-related pathways and induce rapid 
hepatocyte proliferation. This notion is supported 
by the study using a co-culture chamber system, 
which showed that the contact between platelets and 
hepatocytes triggered the secretion of growth factors, 
including HGF, IGF-1 and VEGF from platelets, which 
induced hepatocyte proliferation[20]. 
We suggest the following mechanistic model 
explaining the effect of platelets on liver regeneration. 
Platelets migrating to the injured liver translocate from 
the liver sinusoids to the space of Disse, where, upon 
interaction with hepatocytes, they secrete HGF, IGF-1 
and VEGF, which induce hepatocyte proliferation, 
resulting in liver regeneration. However, this model 
may not be fully applicable to humans, because human 
platelets do not secrete sufficient amounts of HGF[43]; 
therefore, IGF-1 may be the most important platelet-
derived growth factor involved in the restoration of the 
human liver. 
A recent study suggested an additional mechanism 
underlying platelet stimulation of liver regeneration. 
Thus, Kirschbaum et al[78] showed that transfer of 
coding or regulatory RNA could occur between platelets 
and hepatocytes, promoting hepatocyte proliferation. 
However, the role of both mechanisms, i.e. the release 
of growth factors and/or RNA transfer from platelets, 
in liver regeneration needs confirmation in vivo[79,80]. 
EFFECT OF PLATELET TRANSFUSIONS 
ON CLD AND CIRRHOSIS 
Thrombocytopenia is typically treated by platelet 
transfusion, which is suggested to improve liver 
function. However, it has not been established 
whether platelet transfusion can benefit CLD patients 
with thrombocytopenia since the pathogenesis of 
thrombocytopenia in CLD is multifactorial; therefore, 
the published guidelines on platelet transfusion do 
not cover CLD-related platelet loss[49]. As animal 
experiments indicate feasibility of using blood 
IL-6 secretion increased following hepatectomy[62,63] 
triggers STAT3 phosphorylation in hepatocytes, which 
up-regulates the synthesis of acute phase proteins 
as a part of the mechanism restoring the disturbed 
physiological homeostasis[64]. The direct contact of 
platelets with LSECs stimulated LSEC proliferation 
and accelerated DNA synthesis in hepatocytes by 
inducing IL-6 secretion, possibly via sphingosine 
1-phosphate (S1P), a major bioactive lysophospholipid 
released from platelets[29]. S1P is known as a regulator 
of diverse cellular activities, including migration, 
proliferation and cytoskeletal remodeling, and is 
known to induce STAT3 activation by stimulating IL-6 
secretion[65]. Activated platelets secrete high amounts 
of S1P which acts on endothelial cells in the processes 
involving platelet-endothelial interactions, such as 
thrombosis, angiogenesis and atherosclerosis[65,66]. 
Another type of non-parenchymal cell interacting 
with platelets is the Kupffer cells, which constitute 
over 80% of the tissue macrophages found in the 
body and act against gastrointestinal bacteria, 
microbial debris and endotoxins[67]. Upon activation, 
Kupffer cells secrete important growth-stimulating 
cytokines that promote hepatocyte proliferation 
after hepatectomy and induce processes involved 
in hepatic tissue restoration[68]. Kupffer cells are the 
most important source of IL-6 and TNF-α; the latter 
is increased following hepatectomy, suggesting that 
this cytokine as well as its producers (Kupffer cells) 
are implicated in the restoration of hepatic function in 
pathologic conditions. This notion is supported by the 
observations that anti-TNF-α antibodies suppressed 
hepatocyte proliferation[69], while TNF-α receptor-
deficient mice had delayed liver regeneration after 
hepatectomy[70,71] because of decreased production of 
IL-6, which is a key target of TNF-α receptor activation 
in the regenerating liver[52]. As Kupffer cells are the 
most active producers of both TNF-α and IL-6 in the 
liver, it is not surprising that Kupffer cell-depleted 
mice fail to up-regulate TNF-α and IL-6 secretion after 
hepatectomy[72]. 
However, the role of Kupffer cells in liver rege-
neration is controversial. It has been shown that the 
interaction among platelets, Kupffer cells and leukocytes 
promote endothelial cell apoptosis in the liver following 
ischemia/reperfusion[73]. Depletion of Kupffer cells 
decreased platelet adherence in sinusoids in rats 
subjected to ischemia/reperfusion and attenuated 
damage to liver endothelium[74], which is consistent 
with the findings that platelets adhering to Kupffer 
cells during the early period of ischemia/reperfusion 
promoted hepatocyte apoptosis[75]. Although Nakamura 
et al[76] reported that in lipopolysaccharide-injected 
mice, platelets migrate to the space of Disse, which 
is mediated by their interaction with Kupffer cells, 
and then enter hepatocytes, the role of this process 
in hepatic regeneration is unclear. Further studies are 
needed to elucidate the mechanism underlying the 
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transfusion for thrombocytopenia associated with 
chronic liver injuries, clinical trials have been conducted. 
A recent study included patients with CLD and 
cirrhosis (Child-Pugh class A or B) who demonstrated 
thrombocytopenia with platelet counts between 50000 
and 100000/μL; the patients were treated with 10 U 
of platelet concentrate weekly for 12 wk and followed 
up for 9 mo after the last transfusion[33]. Although the 
platelet count did not show a significant increase, a 
marked improvement of liver function was observed, 
as evidenced by higher serum albumin levels 1 and 3 
mo post-transfusion and higher serum cholinesterase 
concentration 9 mo post-transfusion; at the same time, 
serum hyaluronic acid levels indicative of liver fibrosis 
tended to decrease. However, this clinical trial was 
a non-controlled, non-randomized study based on a 
small sample size (6 patients); therefore, randomized 
controlled trials using larger patient cohorts need to be 
conducted in order to conclusively determine clinical 
value of platelet transfusion in CLD.
However, on the other hand, platelet preparations, 
despite recent prolongation of the preservation 
period, can only be used for 4 d due to the need to 
prevent proliferation of bacteria by preservation at 
room temperature. Furthermore, in patients with 
hematologic diseases who require repeated blood 
transfusions, alloantibodies are produced for human 
leukocyte antigens (HLAs) and human platelet antigens 
(HPAs) that differ from the patient’s own antigens, 
thereby triggering platelet transfusion refractoriness 
(PTR). Patients with PTR caused by anti-HLA antibodies 
or anti-HPA antibodies require HLA/HPA-matched 
platelet transfusions; however, securing donors is 
extremely difficult[81]. 
These factors result in an imbalance between 
supply and demand, thus generating interest in 
research that seeks to develop an alternative trans-
fusion source to blood donation. Despite research in 
which hematopoietic stem cells (which are somatic 
stem cells) are used as a source to manufacture 
platelets ex vivo, this research has not been put to 
practical use due to the absence of an ex vivo human 
hematopoietic stem cell amplification method in which 
the cells’ functions can be retained.
Using our independently developed human mesen-
chymal stromal cells, we have succeeded in cultivating 
larger numbers of megakaryocytes, the sources of 
platelet production, than reported in previous studies; 
however, this method has not produced enough 
platelets to serve as a substitute for donated blood[82]. 
Similarly, studies in which umbilical cord blood-derived 
CD34+ cells are used as a source for red blood cell 
production have been unable to amplify these cells ex 
vivo; thus, no technique has yet been developed that 
can produce 1012 red blood cells, the number of red 
blood cells needed for a single transfusion[83]. 
Alternatively, pluripotent embryonic stem cells 
(ES cells) and induced pluripotent stem cells (iPS 
cells)[84] can be grown semipermanently in vitro and 
can resolve the crucial issue of “yielding the number of 
original cells”. In iPS cell-based regenerative medicine, 
post-transplantation cancer is a major concern. In 
response to this concern, safety for platelets and red 
blood cells can easily be ensured with a combination of 
anucleated cells, removal of nucleated cells with a filter 
prior to transfusion, and radiation to eliminate mixed-
in lymphocytes. In addition, banking of iPS cells with 
various HLAs enables the construction of a system for 
stable provision of HLA-matched platelets[85]. 
Furthermore, Ono-Uruga et al[86] have discovered 
that pre-adipocytes endogenously possess the megaka-
ryocyte inducer p45NF-E2 and can induce differentiation 
of megakaryocytes into platelets while increasing 
their own expression of p45NF-E2; they are striving 
to stably and safely produce platelets for transfusion 
from pre-adipocytes for medical applications. However, 
the number of platelets produced by this method is 
currently too low for practical use. 
EFFECT OF TPO-R AGONIST 
ELTROMBOPAG IN CLD
Although platelet increment therapies such as 
splenectomy and platelet transfusion can ameliorate 
CLD and liver cirrhosis, they may also cause serious 
side effects[48,87-90]. Thus, portal vein thrombosis[48,87], 
hemorrhage, infection and injury to the pancreatic 
tail[88] are among surgical complications encountered 
during splenectomy, while the platelet activation 
frequently observed in platelet transfusion may result 
in proinflammatory responses, febrile non-hemolytic 
reactions, and acute lung injury[89,90]. Besides, as we 
indicated earlier, there are reports about detrimental 
effects of platelets on hepatocytes[73-75]. Therefore, 
other approaches to treat thrombocytopenia in CLD 
should be considered. Among them, TPO-R agonists 
eltrombopag and romiplostim, already approved as 
therapeutics for chronic immune thrombocytopenic 
purpura, may also hold promise as treatment for CLD 
and liver cirrhosis. 
Eltrombopag is a low molecular weight, synthetic 
nonpeptidyl drug, whereas romiplostim is a peptide 
containing an IgG Fc fragment in its structure[91]. 
Eltrombopag has already been tested in a phase II 
clinical trial involving patients with hepatitis C-associated 
cirrhosis and concurrent thrombocytopenia to increase 
platelet counts before starting anti-viral therapy with 
peg-interferon and ribavirin, which showed promising 
results[47]. Although eltrombopag is a TPO-R ligand, 
it caused little effect on platelet function and did not 
activate the PI3K/Akt pathway, in contrast to TPO, 
which caused significant platelet activation[92]. 
The safety of using TPO-R (c-Mpl) agonists was 
examined in c-Mpl-expressing leukemia cells. Similar to 
TPO, eltrombopag did not increase but rather inhibited 
proliferation of leukemia cells in vitro, suggesting the 
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lack of tumorigenic side effects[93]. Moreover, TPO had 
no proliferative effect on HCC either in vitro or in vivo[94], 
while eltrombopag induced cell cycle arrest in HCC, 
demonstrating that it may act as a chemotherapeutic 
agent to inhibit the progression of HCC developed 
as a complication of CLD and liver cirrhosis[95]. Thus, 
eltrombopag represents a promising novel candidate 
drug to treat both CLD-related thrombocytopenia and 
associated malignant neoplasm.
To increase platelets in a continuous manner 
and avoid platelet transfusion refractoriness, we con-
ducted an exploratory clinical trial and administered 
eltrombopag for 6 mo. The study included 5 patients 
with both CLD and a hepatitis C virus infection (Child-
Pugh class A) who presented with thrombocytopenia 
(average platelet count 54 × 109/L). All of the patients 
administered eltrombopag maintained platelet counts 
between 10.0 and 15.0 × 1010/L during the 6-mo 
study, and their serum albumin, cholinesterase, alanine 
aminotransferase, T-bilirubin, hyaluronic acid and type 
IV collagen levels, as well as the platelets (%) and 
liver volumes, were stable throughout the clinical trial. 
The liver volumes calculated by computed tomography 
during the clinical trial were also stable, and no new 
cancerous lesions were observed.
However, in contrast to our previous clinical study[33], 
we predicted that the increment values would be 
small because the liver function was representative of 
a heterogeneous population (Figure 1). Additionally, 
recent reports stated that the aging of platelets 
controls TPO production[96]; thus, we concluded that 
the aging and activation of platelets are involved 
in liver regeneration. Therefore, we are planning a 
novel therapy with TPO receptor agonists by using a 
desialylated formulation. In other words, increasing the 
platelet count by using TPO and aging the platelets via 
administration of a desialylated formulation to promote 
liver regeneration could be an effective treatment of 
CLD and liver cirrhosis (Figure 1).
Together with the antitumor effects of eltrombopag 
on hepatocellular carcinoma (HCC) that we previously 
reported[95], we are preparing for eltrombopag clinical 
trials for HCC patients with unmet medical needs and 
who cannot use sorafenib (Figure 2). 
CANCER AND PLATELETS 
Since Trousseau[97] first reported the excessive blood 
coagulation in cancer patients with elevated platelet 
counts in 1865, a large number of studies have been 
conducted on cancer and platelets[98]. 
Cancer development involves the following 
progression: (1) separation from the primary tumor 
and infiltration of blood vessels; (2) transportation 
through blood flow; (3) adhesion to the capillary walls 
of distant organs; (4) extravascular migration; and 
(5) proliferation at the new site to form a metastatic 
lesion. Of course, platelets are involved in almost every 
step of this process.
epithelial-mesenchymal transition 
For epithelial cancers to separate from their primary 
tumor, cells are required to break free from the strong 
cellular adhesion with the surrounding cells and then 
separate and migrate. The process of a cell losing 
its cellular adhesiveness, gaining the mesenchymal 
functions of migration and invasive capacity, and 
becoming resistant to apoptosis is known as epithelial-
mesenchymal transition (EMT). Labelle et al[99] de-
monstrated that platelet-secreted TGF-β and direct 
interactions between cancer cells and platelets can 
induce EMT and promote metastasis. 
Our previous study
Platelet transfusion
Liver cirrhosis ↓
eltrombopag
(TPO receptor agonist)
Platelets ↑
Liver cirrhosis →
eltrombopag
(TPO receptor agonist)
Platelets ↑
Liver cirrhosis ↓
+ Aging (desialylated)
Our planning study
Figure 1  Flow charts of our previous study and our prospective study.
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Protection of cancer cells in rapid flow conditions
Normally, the mass of cancer cells in the circulating 
blood is destroyed by the attack of the immuno-
competent cell and the shear stress in the blood vessel, 
and it is said that only 0.01% of the cancer cells are 
involved in metastasis. However, when platelets are 
activated by cancer cells, if platelets stick around the 
cancer cells and surround the periphery, the possibility 
of survival, as protected from shear stress and attack 
by immunocompetent cells, increases.
Protection from shear stress: Using a shear stress-
induced platelet aggregation measuring device, Egan 
et al[100] demonstrated that elevation of LDH levels 
induced by cell destruction was significantly lower 
when both platelets and cancer cells were present 
compared to the presence of cancer cells alone. 
Protection from natural killer cells: Natural 
killer (NK) cells recognize cells with poor MHC 
class Ⅰ expression as non-self and attack those cells. 
In 1999, Nieswandt et al[101] reported a mechanism 
by which platelets can surround cancer cells and 
physically block access of NK cells in order to protect 
cancer cells from damage. In 2012, Placke et al[102] 
reported that MHC class Ⅰ, which is abundantly 
expressed on platelets, can transfer from the adherent 
platelets to the cancer cells; therefore, cancer cells are 
then recognized as “self” by NK cells and escape injury. 
Besides this, some soluble substances from activated 
platelets reduce NK cell activity, and TGF-β released 
from platelets suppresses the expression of NKG2G on 
NK cells and reduces its cytotoxic activity, as has been 
reported.
Adhesion to blood vessel walls
Various membrane proteins that bind to endothelial 
cells are expressed on platelets; thus, an agglo-
meration of cancer cells and platelets can bind to the 
endothelium of blood vessels and is thought to form 
footholds for metastases. However, it is possible that 
cancer cells could adhere to von Willebrand factor 
and P secretin expressed on platelets that have been 
activated by blood vessel endothelium-mediated 
interactions with GPIb[103-105]. Additionally, both P 
secretin and PSGL-1 are expressed on both platelets 
and blood vessel endothelium, the latter of which may 
become a foothold for metastases.
extravascular migration
Following the agglomeration of cancer cells and 
platelets has bound to the blood vessel endothelium, 
release of platelet granules plays an important role 
during extravascular migration, as demonstrated in 
experiments using either granule content or knockout 
mice incapable of granule release[106,107]. It has been 
reported that ATP released from platelets activated by 
cancer cells binds with purinergic receptors in the blood 
vessel endothelium and elevates intracellular calcium 
via Gq/G11 signaling and increases the permeability 
of the blood vessel endothelial barrier via activation 
of protein kinase C, thereby driving the extravascular 
migration of cancer cells. 
Proliferation at the metastasis site
As a result of the above-mentioned activation, 
platelets release various growth factors, such as VEGF, 
PDGF and bFGF, which are said to promote tumor 
proliferation[106]. Reports indicate that when mice were 
Figure 2  Representation of the mechanism of eltrombopag regarding its effects on liver regeneration, liver fibrosis and hepatocellular carcinoma.
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injected with stomach cancer cell lines and ovarian 
cancer cell lines, and subjected to platelet reduction 
via platelet antibodies, the tumor volume was less 
pronounced[108,109].
There are also reports describing that platelet 
infusion into tumor-bearing mice results in a significant 
increase in the tumor volume and the number of 
Ki67-positive tumor cells, which are indicative of cell 
proliferation[109,110]. On the other hand, there are also 
reports suggesting that the tumor volume does not 
change when platelet reduction is induced in mice 
transplanted with melanoma cell lines[111] and, as in 
the reports described above, that the tumor volume is 
not affected even when TPO is administered to mice 
transplanted with liver cancer cell lines[94]. Based on 
these conflicting data, it is thought that the influence 
of platelets on tumor proliferation is dependent upon 
the histological type and the microenvironment.
The above findings suggest that platelets are 
involved at each stage of cancer metastasis, from 
separation of cancer cells from the primary tumor to 
proliferation at the metastatic site. Therefore, inhibiting 
the platelet-cancer interaction by targeting platelets 
may lead to the development of novel therapeutic 
agents to treat cancer metastasis. Recently, there 
have been reports that aspirin significantly reduced the 
mortality rates of adenocarcinoma but did not inhibit 
the mortality rate for other types of cancer[112,113]. 
Furthermore, the mechanism of action regarding this 
purported anti-metastatic effect of aspirin can also 
be observed in cells other than cancer cells, and the 
increased bleeding tendency with an aspirin regimen is 
problematic.
In other words, it is important to target not 
platelets, which have critical physiological activities, 
but rather cancer-specific platelet activating factors, 
including integrins, cathepsin B, Necl-5, MMP2, GPIb 
and podoplanin, all of which are expressed on cancer 
cells. 
CONCLUSION
This editorial suggests the current perspective of novel 
treatments for liver cirrhosis by using TPO-R agonists 
to increase platelet counts in a clinical setting.
There is significant evidence that platelets play a 
role in improving fibrosis. Upon their release, the ATP 
and ADP within platelet dense granules are degraded 
by HSCs into adenosine, which is incorporated into the 
HSCs.
There are three distinct mechanisms of liver 
regeneration induced by platelets: a cooperative effect 
with LSECs; a cooperative effect with Kupffer cells; and 
a direct effect on hepatocytes. Additionally, platelet 
transfusion improves liver function in patients with 
CLD and cirrhosis. Despite its safety and maintenance 
in increasing platelet counts, administration of the 
TPO-R agonist eltrombopag for 6 mo did not result 
in improvements of liver function in patients with 
CLD. Therefore, we are planning a new approach to 
develop novel strategies with TPO-R agonists and a 
desialylated formulation for treating liver diseases 
for which there are currently no effective treatments 
except transplantation. Of course, it is necessary to 
pay sufficient attention to the onset of thrombosis by 
excessively increasing platelets.
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